Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: a prospective cohort study.
|
| Abstract | OBJECTIVES: Although clinical data have shown that the BNT162b2 vaccine, which is widely used in many countries, is safe and effective as a protection against the SARS-CoV-2 infection, extant research in adverse reactions using real-world data of various sociodemographic characteristics is scant. METHODS: We conducted a prospective cohort study to compare age differences in self-reported reactogenicity of BNT162b2 in Hong Kong. A total of 1,516 participants were intensively followed up for two weeks following both doses of BNT162b2 vaccination, during which their basic demographic, health conditions, and medication information were collected. RESULTS: Results from the generalized mixed model showed that compared with adults aged 18 to 59 years, older adults aged 60 years or above had a lower risk of adverse reactions and adolescents aged 12 to 17 years had a moderately higher risk. CONCLUSIONS: Results of this study should be informative to parents considering BNT162b2 vaccination for their children in that moderately increased reactogenicity compared with adults is anticipated.
|
|---|---|
| Authors | Edward Wai Wa Chan, Miriam Tim Yin Leung, Lauren Ka Wun Lau, Janice Leung, Dawn Lum, Rosa Sze-Man Wong, Xue Li, Celine Sze Ling Chui, Eric Yuk Fai Wan, Carlos King Ho Wong, Esther Wai Yin Chan, Patrick Ip, Ian Chi Kei Wong, Francisco Tsz Tsun Lai |
| Journal | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (Int J Infect Dis) Vol. 116 Pg. 47-50 (Mar 2022) ISSN: 1878-3511 [Electronic] Canada |
| PMID | 34965462 (Publication Type: Journal Article) |
| Copyright | Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!